Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with fusion.

fusion is found in < 1% of de novo acute myeloid leukemia (AML) cases and confers a poor prognosis. This Japanese nationwide survey analyzed patients with AML ( = 22) and mixed phenotype acute leukemia (MPAL) ( = 10) with t(9;22) or who underwent allogeneic hematopoietic cell transplantation (allo-HCT) between 2002 and 2018. The 3-year overall survival (OS) rates were 81.3% and 56.0%, respectively (= 0.15), and leukemia-free survival (LFS) rates were 76.2% and 42.0%, respectively ( = 0.10) in patients with AML and MPAL. The relapse rates were 9.5% and 14.0% ( = 0.93), and the non-relapse mortality (NRM) rates were 14.3% and 44.0%, respectively ( = 0.10) in patients with AML and MPAL. One in 17 patients with AML, with pre-transplant tyrosine kinase inhibitors (TKI), and three in five patients with AML, without pre-transplant TKI, did not achieve complete remission (CR) before allo-HCT ( = 0.024). Among the 20 patients with known disease status after allo-HCT, 95.0% were in hematological or molecular CR. None of the four patients who received post-transplant TKI for prophylaxis or measurable residual disease relapse experienced hematological relapse. In conclusion, our results suggest that pre-transplant TKI could improve disease status before allo-HCT. Moreover, allo-HCT resulted in high OS, high LFS, low relapse, and low NRM rates in patients with AML with .